



PATENT

Attorney Docket No.: 8321-113

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent application of :
Jay S. Schneider :
Serial No.: 10/660,090 : Group Art Unit:
Not yet assigned :
Filed: September 11, 2003 : Examiner:
Not Yet Assigned :
For: METHODS AND KIT FOR TREATING :
PARKINSON'S DISEASE :
:

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith are copies of the references listed in the accompanying PTO Form 1449.

The Examiner is respectfully requested to review the items listed on the PTO Form 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute Form 1449, and return one copy to the undersigned.

This Information Disclosure Statement should not be construed as a representation

**CERTIFICATE OF MAILING
UNDER 37 C.F.R. 1.8(a)**

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date indicated below, with sufficient postage, as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

BY

Debbie M. Collins

DATE:


10/28/2003


that the cited references are material or that more relevant prior art does not exist.

This statement is being submitted before receipt of any office action on the merits. Thus, no fee is due for the filing of this paper. However, if a fee is due, please charge deposit account 50-0573.

Respectfully submitted,

JAY S. SCHNEIDER

BY: 
DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH, LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
Telephone: (215) 988-3312
Fax: (215) 988-2757
Attorney for Applicant

SUBSTITUTE FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 8321-113	SERIAL NO. 10/660,090
 INFORMATION DISCLOSURE CITATION				APPLICANT: Jay S. Schneider	
				FILING DATE September 11, 2003	GROUP Not yet assigned

U.S. PATENT DOCUMENTS


EXR. INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
.	AA	2002/0035145	03/2002	Tsai et al.	514	472	
	AB	5,668,117	09/1997	Shapiro	514	55	
	AC	4,904,681	02/1990	Cordi et al.	514	380	
	AD	6,284,776	09/2001	Meltzer	514	326	
	AE	5,260,324	11/1993	Cordi et al.	514	376	
	AF	6,294,583	11/2001	Fogel	514	665	
	AG	6,417,210	07/2002	Melamed et al.	514	367	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES <input type="checkbox"/> NO <input type="checkbox"/>	
	AF	WO 01/12190	02/2001	WO				
	AG	WO 99/52519	04/1999	WO				
	AH	WO 97/39797	04/1997	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AI	Laake K. Oeksengaard AR, (2002) "D-cycloserine for Alzheimer's disease," <i>The Cochrane Library</i> Issue 4
AJ	Wadie Najm, M.D. (2002), "Using Complementary Treatments in Dementia," <i>Center for clinical Age Management, Inc.</i>
AK	Sophie Erhardt, (2001), "Importance of endogenous kynurenic acid in brain catecholaminergic processes and in the pathophysiology of schizophrenia," <i>Doctor's Thesis from Karolinska Institutet</i> 91:628-4889-5.
AL	V. Lelong et al., (2001), "RS 67333 and D-cycloserine accelerate learning acquisition in the Rat.," <i>Neuropharmacology</i> 41:517-522. (abstract only)
AM	B.N.M. van Berckel et al., (1998), "original investigation: The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers," <i>Psychopharmacology-Abstract</i> , 138:190-197. (abstract only)
AN	P. Riekkinen Jr. et al., (1998), "D-cycloserine, a partial NMDA receptor-associated glycine-B site agonist, enhances reversal learning, but a cholinesterase inhibitor and nicotine has no effect," <i>NeuroReport</i> , 9:3647-3651. (abstract only)
AO	J.F. Disterhoft et al., (1997), "Mechanisms of associative learning in young and aging hippocampus," <i>Journal of Physiology</i> , 501:6S.



AP	Robert van Reekum, MD FRCPC et al., (1997), "Cognition-Enhancing Drugs in Dementia: A Guide to the Near Future," <i>Can J Psychiatry</i> , 42:35S-50S.
AQ	J.W. Allen, B.S., (1996), "A Review of the Actions of D-cycloserine, a Putative Nootropic Agent, at the NMDA Receptor Complex-Associated Glycine Binding Site," <i>MJM</i> , 2:40-50.
AR	R.B. Rosse et al., (1996), "D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia," <i>Clin Neuropsychopharmacol</i> , 19:444-450. (abstract only)
AS	M. Pitkanen et al., (1995), "The effects of d-cycloserine, a partial agonist at the glycine binding site, on spatial learning and working memory in scopolamine-treated rats," <i>J Neural Transm Park Dis Dement</i> , 9:133-144. (abstract only)
AT	"Treatment of Negative Symptoms in Schizophrenia," <i>Fiscal Year 2000 NIH GPRA Research Program Outcomes</i> , p. 465. (abstract only)
AU	("Psychosis in Late Life, Ongoing Research," <i>Geriatric Consultant Resources LLC</i> , accessed from http://www.gcrweb.com/PsychosisDSS/clinical/pyalt.html on Jan. 16, 2003
AV	Donald Goff, M.D., "Glycine and D-Cycloserine in Schizophrenia," <i>NIMH Study ID No. MH57708</i> study started 1998/completed 2002; record accessed on Jan. 16, 2003 from http://www.clinicaltrials.gov/show/NCT00000372 (abstract only)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.